Later, the criteria for disclosure of Adverse Drug Reaction Report Forms were revised by Notification No. 4 of the Federation of Pharmaceutical Manufacturers' Associations of Japan (FPMAJ) dated January 6, 2004. Notification No. 0330011 of the PMDA dated March 30, 2011 specifies points to consider in the disclosure of information related to new drug approval reviews and subsequently issued Notification No. 0325-(1) of the Evaluation and Licensing Division, PFSB dated March 25, 2013 partially modified the procedures for public disclosure.